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ARTICLE
Odds of Acute Kidney Injury in Patients Receiving 
Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study 
Within the Department of Veterans Affairs
S. Scott Sutton1,2,* , Joseph Magagnoli1,2, Tammy H. Cummings2 and James W. Hardin2,3
Preclinical and clinical data of dipeptidyl peptidase 4 (DPP-4) inhibitors have demonstrated discordant data regarding acute 
kidney injury (AKI). Therefore, we aimed to evaluate the association between DPP-4 use and AKI. This cohort study utilized 
data from the Department of Veterans Affairs evaluating patients diagnosed with type 2 (T2) diabetes with a DPP-4 inhibitor 
and compared with nondiabetic and diabetic patients. The primary end point is the development of AKI, and statistical analy-
ses were performed to examine the association. DPP-4 use is associated with a lower odds of AKI compared with diabetics 
(adjusted odds ratio (OR) = 0.39; 95% confidence interval (CI) = 0.32–0.48) and nondiabetics (OR = 0.64; 95% CI = 0.52–0.79). 
DPP-4 use in patients with T2 diabetes mellitus is associated with lower odds of AKI within 120 days compared with nondia-
betic and diabetic controls when adjusting for study covariates.
Diabetes affects more than 29 million people in the United 
States, and the majority of diabetes cases are type 2 diabe-
tes mellitus (T2DM).1 Diabetes is a risk factor for acute kid-
ney injury (AKI), and AKI episodes may lead to electrolyte 
abnormalities, pulmonary edema, chronic kidney disease, 
and cardiovascular complications.2–4 Dipeptidyl peptidase 
4 (DPP-4) inhibitors are a class of oral hypoglycemic med-
ications that are used to manage patients with T2DM.5–8 
DPP-4 is an enzyme expressed on the surface of most 
cell types that deactivates bioactive peptides, including 
glucagon-like peptide-1 (GLP-1). DPP-4 inhibitors affect 
glucose control through enhancement of glucose-depen-
dent insulin secretion, slowed gastric emptying, and re-
duction of postprandial glucagon and of food intake. DPP 
inhibitors are utilized as adjunctive drug therapy or mono-
therapy for patients inadequately controlled or who cannot 
take/tolerate other oral diabetes medications. Because the 
DPP-4 enzyme is also expressed on non-GLP-1 cell types, 
nondiabetes medication effects of the DPP-4 inhibitors are 
possible. For example, DPP-4 is also bound on the kidney 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Because the dipeptidyl peptidase 4 (DPP-4) enzyme 
is expressed on non-glucagon-like peptide-1 cell types, 
nondiabetes medication effects of the DPP-4 inhibitors 
are possible. Preclinical and clinical data for DPP-4 in-
hibitors have demonstrated a nephroprotective effect; 
however, clinical data have also demonstrated that DPP-4 
inhibitor use was associated with a higher risk of hospitali-
zation for acute kidney injury (AKI).
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  The purpose of this study is to evaluate patients 
with type 2 diabetes mellitus with a prescription for a 
DPP-4 inhibitor vs. diabetic and nondiabetic patients 
and the associated odds for developing AKI. Research 
question: What are the odds of AKI in patients  
with diabetes receiving DPP-4 inhibitors compared 
with diabetics not receiving DPP-4 inhibitors and 
nondiabetics?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  This study used a large nationwide cohort of US Veterans 
to examine the association of AKI between DPP-4 inhibi-
tors and matched control patients. This study adds addi-
tional literature to previous published discordant results.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
✔  This study can assist prescribers and payers in un-
derstanding real-world experience with this medication. 
There were lower odds of AKI in the DPP-4 cohort com-
pared with the diabetic and nondiabetic controls when 
using adjusted models. However, future research should 
be considered in understanding the risks and benefits of 
DPP-4 use and the occurrence of AKI.
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proximal tubular cell, and microvesicle-bound DPP-4 se-
creted from tubular epithelial cells is found in the urine and 
may be an early marker of kidney damage.9 Additionally, 
renal effects of DPP-4 inhibitors may be mediated by in-
creased GLP-1 levels.10 In addition to the pancreas, the 
GLP-1 receptor is expressed in glomerular endothelial cells, 
and renal effects of DPP-4 inhibitors are, in part, mediated 
by GLP-1 levels.11 However, the exact role and importance 
of the mechanism of kidney effects relating to the DPP-4 
enzyme or DPP-4 inhibitors are not completely understood. 
Preclinical and clinical data for DPP-4 inhibitors have 
demonstrated a nephroprotective effect.12–15 However, 
there have also been clinical data that demonstrated DPP-4 
inhibitor use was associated with a higher risk of hospital-
ization for AKI.16 The discordant study results warrant the 
need for more research evaluating DPP-4 inhibitors and 
AKI. Therefore, the purpose of this study is to evaluate pa-
tients with T2DM with a prescription for a DPP-4 inhibitor 
vs. diabetic and nondiabetic patients and the associated 
odds for developing AKI within the Department of Veterans 
Affairs (VA) Veterans Health Administration system.
METHODS
Data
This retrospective cohort study was conducted using data 
from the Department of Veterans Affairs. The Veterans 
Affairs Informatics and Computing Infrastructure was uti-
lized to obtain individual-level information on demograph-
ics, administrative claims, and pharmacy dispensation. The 
completeness, utility, accuracy, validity, and access meth-
ods are described on the VA website, http://www.virec.
resea rch.va.gov. The study was conducted in compliance 
with the Department of Veterans Affairs’ requirements and 
received institutional review board and research and devel-
opment approval. The study utilized diagnosis International 
Classification of Disease 9th revision (ICD-9-CM) data 
from October 1999 to September 2015, laboratory data 
from January 2001 to June 2016, and pharmacy data from 
December 1999 to June 2016.
Cohort selection
Cases were defined as patients who were diagnosed with 
T2DM (during October 1999 to September 2015) and had 
a prescription for a DPP-4 inhibitor (including sitagliptin, 
saxagliptin, or linagliptin) between the dates June 2005 
and February 2016. The study index period for the DPP-4 
cases was the earliest date the patient was on a DPP-4 and 
had an estimated glomerular filtration rate (eGFR) labora-
tory measure. The eGFR is a calculated laboratory from 
the patients’ medical record and was captured via claims 
data by Logical Observation Identifiers Names and Codes 
code 33914. Nondiabetic controls were defined as patients 
who never had an ICD-9-CM diagnosis of T2DM and never 
had an A1c laboratory result. Uncontrolled blood sugar 
was defined as an A1c value ≥7 for the nondiabetic con-
trols. Diabetic non-DPP-4 controls were defined as those 
who had a diagnosis of T2DM but never had a prescrip-
tion for a DPP-4 inhibitor. To ensure adequate medical sur-
veillance and baseline kidney function, patients who never 
had an eGFR measure while on a DPP-4 were excluded. 
Furthermore, controls who never had an eGFR laboratory 
result during the study, June 2005 to February 2016, were 
excluded.
Matching
A matching algorithm was utilized that matched DPP-4 
cases to controls. A variable number of matched controls 
per case was utilized, with one control being the minimum 
and seven controls as a maximum. Controls were exact 
matched on age at index, race, sex, and constrained con-
trols to be within 10 mL/minute of baseline eGFR. Control 
baseline eGFR measures were also required to be in the 
same month and year as their matched case.
AKI outcome
Cases and controls were followed from index to 120 days 
or AKI incident, whichever occurred first. Specifically, AKI 
was identified from an outpatient acute kidney diagnosis 
using  ICD-9-CM: values were 584 (acute kidney failure), 
584.5 (acute kidney failure with lesion of tubular necro-
sis), 584.6 (acute kidney failure with lesion of renal cortical 
necrosis), 584.7 (acute kidney failure with lesion of renal 
medullary necrosis), 584.8 (acute kidney failure with other 
specified pathological lesion in kidney), and 584.9 (acute 
kidney failure, unspecified).
Study variables
In addition to our primary predictor (DPP-4 inhibitor use), 
covariates were utilized to account for possible differences 
in demographic, disease burden, pharmacy, and labora-
tory results between the cohorts. Demographic variables 
included age, sex, and race coded as white, black, other/
unknown. The Charlson comorbidity index was utilized to 
account for differences in disease burden. The Charlson 
index utilizes all outpatient claims for the 1  year preced-
ing the study index. Additionally, other pharmacy medica-
tions were evaluated and included metformin use during 
the follow-up period, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and proton pump inhibitors (PPIs).
Statistical analysis
The statistical analysis occurred in two steps. The initial step 
utilized statistical tests to compare baseline characteristics 
between the DPP-4 and control cohorts. For continuous 
variables, such as age, eGFR, and the Charlson comorbid-
ity index, we utilized the F-test from the analysis of variance 
results. All categorical variables were analyzed using the χ2 
test. In the second step, we estimated logistic regression 
models to examine the association between DPP-4 use and 
AKI. We estimate three models: (i) unadjusted, with only the 
treatment indicator (diabetic DPP-4, diabetic non-DPP-4, 
and nondiabetic); (ii) a second adjusted for the Charlson 
index; and (iii) a model with all covariates (which included 
treatment indicator, Charlson index, baseline eGFR, un-
controlled A1c, sex, race, age, PPI use, NSAID use, met-
formin use, and index year). Unadjusted odds of AKI within 
120 days for comparisons between cohort groups using a 
Bonferroni multiplicity adjusted interval were also tested for 
each model in this step. All data management and matching 
was done with SAS enterprise guide 7.1 (SAS Institute Cary, 
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NC), and all statistical analysis was done using R (R Core 
Team 2016, Vienna, Austria).
RESULTS
A total of 363,873 patients met all the study criteria. Of 
these, 250,269 patients made up the nondiabetic control 
group, 77,722 the diabetic non-DPP-4 group, and 35,882 
the DPP-4 inhibitor cohort. Table 1 displays the summary 
statistics for the three cohorts. The DPP-4 and control 
cohorts are clinically similar in terms of age (66.7 (10.1) 
vs. 66.8 (9.9) vs. 66.5 (10.2)), race (68% white), and sex 
(96% men). The DPP-4 cohort, on average, has a lower 
eGFR measure at index (69.5 (24.4) vs. 69.8 (23.3) vs. 72.2 
(22.9) mL/minute). The diabetic non-DPP-4 control group, 
on average, had a higher Charlson index (2.8 (2.3) vs. 
2.5 (1.9) vs. 0.8 (1.5)) compared with the diabetic DPP-4 
cases and nondiabetic controls. Approximately 56% of 
the DPP-4 cohort had an uncontrolled A1C (defined as 
A1c ≥ 7) at baseline, and 55% were on metformin during 
the follow-up period. Additionally, 14% of the DPP-4 and 
diabetic non-DPP-4 cohorts and 13% of the nondiabetic 
control cohort had a prescription for NSAIDs, whereas 
32% of both DPP-4 and diabetic non-DPP-4 cohorts 
and 21% of the nondiabetic controls had a prescription 
for PPIs. Of the patients on a DPP-4 inhibitor, 61.8% of 
patients had a prescription for saxagliptin, 44.8% had a 
prescription for sitagliptin, and 12.9% had a prescription 
for linagliptin. Patients may have had a prescription for 
more than one DPP-1, and as a result, the percentages do 
not sum to 100.
Table 2 presents the occurrence of AKI within 120 days 
for each cohort. The DPP-4 cohort had 274 incidents of AKI 
equaling 7.63 (95% confidence interval (CI) =  6.74–8.52) per 
1,000 people, the diabetic non-DPP-4 cohort had 21,784 
incidents of AKI at 22.95 (95% CI = 21.98–24.04) incidents 
per 1,000 people, and the nondiabetic cohort had 1,786 in-
cidents of AKI equaling 7.13 (95% CI = 6.80–7.45) incidents 
per 1,000 people.
The unadjusted  logistic regression (Table 3, model 1) 
demonstrates that patients with diabetes not on a DPP-4 
inhibitor had a 3.05-fold increased odds of AKI compared 
with diabetics on a DPP-4 within 120  days (odds ratio 
(OR)  =  3.05; 95% CI  =  2.69–3.47), whereas there was no 
Table 1 Patient characteristics
Diabetic non­DPP­4 Diabetic DPP­4 Nondiabetic P value
Variable N = 77,722 N = 35,882 N = 250,269
Age, mean (SD) 66.8 (9.9) 66.7 (10.1) 66.5 (10.2) < 0.001
Race
Black 13,451 (17.3%) 6,009 (16.7%) 41,390 (16.5%) < 0.001
Other/unknown 11,274 (14.5%) 5,401 (15.1%) 38,386 (15.3%)
White 52,997 (68.2%) 24,472 (68.2%) 170,493 (68.1%)
Sex
Male 75,220 (96.8%) 34,484 (96.1%) 240,436 (96.1%) < 0.001
Baseline eGFR, mean (SD) 69.8 (23.3) 69.5 (24.4) 72.2 (22.9) < 0.001
Charlson index, mean (SD) 2.8 (2.3) 2.5 (1.9) 0.8 (1.5) < 0.001
Uncontrolled A1c 23,326 (30.0%) 20,194 (56.3%) 0 (0%) < 0.001
NSAID prescription 11,013 (14.2%) 5,064 (14.1%) 33,682 (13.5%) < 0.001
PPI prescription 25,164 (32.4%) 11,325 (31.6%) 52,263 (20.8%) < 0.001
Metformin prescription 28,222 (36.3%) 19,742 (55.0%) 0 (0%) < 0.001
Index year
2005 15 (0.02%) 7 (0.02%) 89 (0.03%) 0.24
2006 27 (0.035%) 13 (0.036%) 159 (0.064%)
2007 348 (0.448%) 161 (0.449%) 1,162 (0.464%)
2008 1,850 (2.38%) 864 (2.41%) 6,042 (2.41%)
2009 2,958 (3.81%) 1,367 (3.81%) 9,522 (3.805%)
2010 3,976 (5.12%) 1,840 (5.13%) 12,852 (5.14%)
2011 5,901 (7.59%) 2,700 (7.53%) 18,660 (7.46%)
2012 8,503 (10.94%) 3,926 (10.94%) 27,086 (10.82%)
2013 8,377 (10.78%) 3,864 (10.78%) 26,553 (10.61%)
2014 14,938 (19.22%) 6,897 (19.22%) 48,003 (19.18%)
2015 25,814 (33.21%) 11,923 (33.23%) 83,993 (33.56%)
2016 5,015 (6.45%) 2,320 (6.47%) 16,148 (6.45%)
DPP-4 medicationa
Saxagliptin – 22,207 (61.8%) –
Sitagliptin – 16,092 (44.8%) –
Linagliptin – 4,664 (12.9%) –
DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; NSAID, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.
aPercentages do not equal 100 because select patients may have received different DPP inhibitors.
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statistically significant difference between the nondiabetic 
control group and the diabetic DPP-4 users (OR = 0.93; 95% 
CI  =  0.82–1.06). However, the second logistic regression 
model was adjusted for the Charlson comorbidity index as 
a covariate and demonstrated that both diabetics not on a 
DPP-4 inhibitors and nondiabetic controls were associated 
with a higher odds of AKI within 120 days compared with 
the diabetics on a DPP-4 (OR = 2.55; 95% CI = 2.24–2.9 
and OR = 1.7; 95% CI = 1.49–1.94, respectively). This model 
also revealed that as the Charlson index increases, the 
odds of AKI also increase (OR = 1.38; 95% CI = 1.37–1.40). 
Additionally, a third logistic regression model was utilized that 
was adjusted for all study covariates and demonstrates that 
diabetic non-DPP-4 inhibitors and nondiabetics are associ-
ated with a higher odds of AKI within 120 days (OR = 2.78; 
95% CI = 2.43–3.17 and OR = 1.32; 95% CI = 1.14–1.53, 
respectively). Model 3 also demonstrates that (i) higher val-
ues of the Charlson comorbidity index were associated with 
an increase in the odds of AKI (OR = 1.26; 95% CI = 1.24–
1.27); (ii) higher baseline eGFR values are associated with 
a lower odds of AKI (OR = 0.96; 95% CI = 0.96–0.96); and 
(iii) compared with black patients, both white (OR  =  0.76; 
95% CI = 0.70–0.83) and other/unknown (OR = 0.60; 95% 
CI = 0.53–0.68) have a lower odds of AKI.
Table 4 presents the results from the unadjusted odds of 
AKI within 120 days for comparisons between cohort groups 
using the Bonferroni multiplicity adjusted interval. When 
comparing DPP-4 cohort with diabetic non-DPP-4 controls, 
we found that DPP-4 use was associated with a lower odds 
AKI (unadjusted OR  =  0.33; 95% CI  =  0.27–0.4; adjusted 
OR = 0.34; 95% CI = 0.28–0.42). Comparing the DPP-4 co-
hort with the nondiabetic controls, we found that the odds of 
AKI in the DPP-4 cohort was not statistically significantly dif-
ferent in the unadjusted model (OR = 1.07, 95% CI = 0.88–
1.3), yet was statistically significant with a lower odds of AKI 
within 120  days in the adjusted models (OR  =  0.59, 95% 
CI = 0.48–0.71 and OR = 0.64, 95% CI = 0.52–0.79). Finally, 
in comparing the diabetic non-DPP-4 controls to the non-
diabetic cohort, we found that the diabetic non-DPP-4 co-
hort had higher odds of AKI in both unadjusted (OR = 3.27; 
95% CI = 2.96–3.61) and adjusted models (OR = 1.5; 95% 
CI = 1.34–1.67; OR = 1.86; 95% CI = 1.65–2.1).
DISCUSSION
This retrospective analysis of US veterans compared a 
national cohort of patients with T2DM and a DPP-4 inhib-
itor prescription with matched controls of nondiabetic pa-
tients. Patients were followed for an episode of AKI within 
120 days. The goal of the study was to evaluate the associa-
tion of DPP-4 inhibitor on the odds of AKI. This study found 
that of the cohort groups, the diabetic non-DPP-4 control 
cohort (22.95 (95% CI  =  21.98–24.04) per 1,000 patients) 
had the highest rate of AKI compared with the DPP-4 co-
hort (7.63 (95% CI = 6.74–8.52) per 1,000 patients) and the 
nondiabetic control cohort (7.13 (95% CI = 6.80–7.45) per 
Table 2 Occurrence of AKI within 120 days
Cohort Total AKI Per 1,000 people (95% CI
a)
Diabetic non-DPP-4 1,784 22.95 (21.98–24.04)
Diabetic DPP-4 274 7.63 (6.74–8.52)
Nondiabetic 1,786 7.13 (6.80–7.45)
AKI, acute kidney injury; CI, confidence interval; DPP-4, dipeptidyl pepti-
dase 4.
aBootstrapped 95% CI.
Table 3 Odds of AKI within 120 days
Variable
Model 1 Model 2 Model 3
OR (95% CI) OR (95% CI) OR (95% CI)
(Intercept) 0.01 (0.01–0.01) 0.00 (0.00–0.00) 0.38 (0.26–0.55)
Diabetic DPP-4 (baseline)
Diabetic non-DPP-4 3.05 (2.69–3.47) 2.55 (2.24–2.9) 2.78 (2.43–3.17
Nondiabetic 0.93 (0.82–1.06) 1.7 (1.49–1.94) 1.32 (1.14–1.53)
Charlson index 1.38 (1.37–1.40) 1.26 (1.24–1.27)
Baseline eGFR 0.96 (0.96–0.96)
Uncontrolled A1c 0.92 (0.84–1.02)
Sex (female baseline)
Male 1.19 (0.95–1.48)
Race (black baseline)
Other/unknown 0.6 (0.53–0.68)
White 0.76 (0.7–0.83)
Age 0.98 (0.98–0.99)
PPI use 0.71 (0.66–0.77)
NSAID use 0.58 (0.49–0.68)
Metformin use 0.41 (0.35–0.48)
Index year 0.92 (0.91–0.94)
AKI, acute kidney injury; CI, confidence interval; DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; NSAID, nonsteroidal anti-inflam-
matory drugs; PPI, proton pump inhibitor.
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1,000 patients). Diabetic non-DPP-4 controls had higher 
odds of AKI within 120 days compared with both the DPP-4 
cohort and nondiabetic controls in all models. Additionally, 
the unadjusted logistic regression model demonstrates that 
DPP-4 inhibitors are not statistically different compared 
with nondiabetic controls, and a decreased odds of AKI 
compared with diabetic non-DPP-4 controls. In addition, 
in the unadjusted model, diabetic non-DPP-4 cohort had 
an over threefold increased odds of AKI within 120  days 
compared with the nondiabetic cohort. Furthermore, the 
fully adjusted model 3 demonstrated that the DPP-4 cohort 
had 66% and 36% lower odds of AKI within 120 days when 
compared with both control groups (diabetic non-DPP-4 
and nondiabetics, respectively). Further, the diabetic non-
DPP-4 cohort had an almost two fold increase in odds of 
AKI within 120 days compared with the nondiabetic cohort.
Systematic reviews and meta-analyses of the safety, ef-
ficacy, and tolerance of DPP-4 inhibitors on patients with 
T2DM calls for continued research and investigations on the 
effects of DPP-4 inhibitor use.17–20 In a pooled analysis of ran-
domized clinical studies of patients with T2DM on the DPP-4 
inhibitor sitagliptin, the researchers concluded that the drug 
was tolerable up to 76 weeks and 2 years.21,22 However, pre-
clinical and clinical studies have focused on the association 
of AKI related to DPP-4 inhibitors and have found discor-
dant results. Preclinical animal experimental studies have 
demonstrated a nephroprotective effect of DPP-4 inhibitors. 
Rats given an oral dose of DPP-4 sitagliptin (200  mg/kg/
day) for 8 weeks had a renoprotective effect on their rem-
nant kidneys.23 Diabetic rats compared with nondiabetic rats 
treated with a DPP-4 inhibitor (vildagliptin) had lower body 
weight, plasma insulin levels, and serum creatinine levels. 
Additionally, the existence of interstitial expansion, glomer-
ulosclerosis, and the thickening of the glomerular basement 
membrane attenuated renal injury in diabetic rats admin-
istered DPP-4 inhibitors.13 DPP-4 inhibition resulted in a 
dose-dependent protective effect on kidney function in a rat 
model, as shown by reduced serum creatinine levels after 
renal ischemia–reperfusion injury. Additionally, the reduced 
serum creatinine levels were accompanied by morphological 
protection indicated by a decrease in tubular necrosis.15
Select clinical evaluations have demonstrated consistent 
results of the preclinical animal studies on the association 
of AKI with DPP-4 inhibitors. The DPP-4 inhibitor linagliptin 
was not associated with increased kidney disease risk com-
pared with placebo in individual patient-level data of pooled 
analysis of 13 phase II or III clinical trials.24 DPP-4 inhibitors 
were associated with reduced risk of mild and severe forms 
of AKI among patients with incident diabetes in a nationally 
representative cohort in Taiwan.25 Additionally, a retrospec-
tive cohort study of a large medical and pharmacy claims 
database demonstrated that there was not an association 
between the use of sitagliptin and AKI.26 In contrast, there 
are reports of an increased association of AKI and DPP-4 
inhibitors. The US Food and Drug Administration has re-
ported episodes of acute worsening of renal function follow-
ing exposure to inappropriate doses of sitagliptin in patients 
with renal insufficiency where there has been inappropri-
ate dose adjustment.27 Additionally, a nested case-control 
study conducted using Taiwan’s National Health Insurance 
Research Database demonstrated that those using DPP-4 
inhibitors had an increased risk of AKI compared with 
nonusers.16
Our study results are consistent with the preclinical ani-
mal models and clinical studies that demonstrate a protec-
tive effect of DPP-4 inhibitor use on AKI. Our study provides 
value to the current literature regarding DPP-4 inhibitors and 
AKI because of previous discordant results. We utilized a 
different patient population to evaluate the external validity 
and generalizability of previous studies. Our large sample 
size utilizing matched controls provides additional evidence 
that DPP-4 inhibitors may have another role in addition to 
managing patients’ blood glucose levels. Although our study 
has a significant number of strengths, there are several lim-
itations that are common to claims database studies of like 
methodology. Because this study was retrospective and ob-
servational, unmeasured confounders may have affected the 
results, despite matching of key covariates between cohorts. 
For example, there is a significant difference in the utilization 
of metformin between the DPP4 and non-DPP4 cohorts. 
Therefore, it is possible the patients on DPP4/metformin 
could have received more stringent care, and this could 
have influenced the outcome. The use of antihypertensive 
medications was not evaluated, and the outcome of blood 
pressure control through an antihypertensive may have had 
an influence on renal outcomes. Our study variable was the 
utilization of a DPP inhibitor and not the dose. However, the 
dose and/or existing renal function of the patient could have 
impacted the results. Specifically, the US Food and Drug 
Administration has reported episodes of acute worsening 
of renal function following exposure to inappropriate doses 
of sitagliptin in patients with renal insufficiency where there 
has been inappropriate dose adjustment.27 Additionally, the 
study population was predominantly middle-to older-aged 
white men; therefore, our findings may not be generalizable 
to patients of different age groups or sexes. Additionally, 
only the association of DPP-4 inhibitors and AKI were stud-
ied; therefore, causality or mechanisms could not be inves-
tigated. However, our association data are consistent with 
previously conducted preclinical studies evaluating mech-
anisms. Preclinical studies suggest a glomerular and/or tu-
bular mechanism of kidney injury; however, the exact role 
Table 4 Odds of AKI within 120 days: Comparisons between cohort 
groups
Contrast
Model 1 Model 2 Model 3
OR (95% 
CIa )
OR (95% 
CIa )
OR (95% 
CIa )
Diabetic DPP-4 vs. 
diabetic non-DPP-4
0.33 
(0.27–0.4)
0.39 
(0.32–0.48)
0.34 
(0.28–0.42)
Diabetic DPP-4 vs. 
nondiabetic
1.07 
(0.88–1.3)
0.59 
(0.48–0.71)
0.64 
(0.52–0.79)
Diabetic non-DPP-4 
vs. nondiabetic
3.27 
(2.96–3.61)
1.5 
(1.34–1.67)
1.86 
(1.65–2.1)
AKI, acute kidney injury; CI, confidence interval; DPP-4, dipeptidyl pepti-
dase 4; OR, odds ratio.
aBonferroni multiplicity adjusted interval.
703
www.cts-journal.com
Acute Kidney Injury and DPP4 Inhibitors
Sutton et al.
and importance of the mechanism of kidney effects relat-
ing to the DPP-4 enzyme or DPP-4 inhibitors are not com-
pletely understood. Further research is needed to continue 
the evaluation of AKI in patients receiving DPP4 inhibitors to 
further our understanding of the association, mechanisms, 
and clinical application of AKI episodes.
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